WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation ...

A plain-talk shelf-life strategy for US retailers to reduce shrink, protect gross margin, and improve sell-through without relying on deep discounting.

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...

HONG KONG, HONG KONG , HONG KONG, January 21, 2026 /EINPresswire.com/ -- As skincare science rapidly evolves toward ...

How Ropack’s evolution from service provider to strategic CMO partner reflects broader shifts in manufacturing, packaging, and quality expectations.

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ...

The Dangote group described the agreements as a major milestone in the refinery's expansion drive and a proactive step to secure the vast energy requirements needed to support increased production ...

On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...

Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop and manufacture multiple bi- and multi-functional fusion programs from ...